Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Tamoxifen 25Radiotherapy 15Chemotherapy, Adjuvant 11Anastrozole 11Specimen Handling 10Neoadjuvant Therapy 8Letrozole 8Biopsy 7Radiation 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6Immunohistochemistry 5Gene Expression Profiling 5exemestane 4Surgical Procedures, Operative 4Sentinel Lymph Node Biopsy 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Psychiatric Rehabilitation 4Mass Spectrometry 4Early Intervention, Educational 4Counseling 4afimoxifene 3Trastuzumab 3Surveys and Questionnaires 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation Dose Hypofractionation 3Methods 3Mastectomy 3High-Energy Shock Waves 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × 4-hydroxy-N-desmethyltamoxifen × Clear all
NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡